Cargando…

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group

PURPOSE: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and survival, remains a major challenge. Our group ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Maximilian, Diefenhardt, Markus, Nicolas, Adele M., Rödel, Franz, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Greten, Florian R., Rödel, Claus, Fokas, Emmanouil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018120/ https://www.ncbi.nlm.nih.gov/pubmed/35449546 http://dx.doi.org/10.1016/j.ctro.2022.04.003

Ejemplares similares

Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial
por: Diefenhardt, Markus, et al.
Publicado: (2022)

Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited
por: Diefenhardt, Markus, et al.
Publicado: (2022)

Overall Survival After Treatment Failure Among Patients With Rectal Cancer
por: Diefenhardt, Markus, et al.
Publicado: (2023)

Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center
por: Zimmermann, Marcus, et al.
Publicado: (2022)

Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?
por: Rödel, Claus, et al.
Publicado: (2017)

Image-guided radiotherapy in an orthotopic mouse model of rectal cancer
por: Nicolas, Adele M., et al.
Publicado: (2022)

Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Eine Monotherapie mit Immuncheckpointblockade führt bei Patienten mit Rektumkarzinom und Mikrosatelliteninstabilität zur klinischen Komplettremission
por: Diefenhardt, Markus, et al.
Publicado: (2022)

C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy
por: Martin, Daniel, et al.
Publicado: (2019)

Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer
por: Martin, Daniel, et al.
Publicado: (2017)

C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
por: Frey, Alina, et al.
Publicado: (2022)

Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma
por: Martin, Daniel, et al.
Publicado: (2020)

Are We There Yet? The Value of Deep Learning in a Multicenter Setting for Response Prediction of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy
por: Wichtmann, Barbara D., et al.
Publicado: (2022)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Management of anal cancer patients – a pattern of care analysis in German-speaking countries
por: Martin, Daniel, et al.
Publicado: (2020)

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
por: Lee, Sung Uk, et al.
Publicado: (2013)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer
por: Fokas, Emmanouil, et al.
Publicado: (2015)

Präoperative Therapie des Rektumkarzinoms – Kritische Anmerkungen zur amerikanischen PROSPECT-Studie
por: Fokas, Emmanouil, et al.
Publicado: (2023)

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
por: Balermpas, P, et al.
Publicado: (2014)

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
por: Balermpas, P, et al.
Publicado: (2014)

Neoadjuvant chemoradiotherapy with capecitabine based regimen in locally advanced rectal cancer: A retrospective study
por: Li, Fei, et al.
Publicado: (2023)

Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy
por: Fleischmann, Max, et al.
Publicado: (2019)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
por: Li, Anchuan, et al.
Publicado: (2022)

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis
por: Liu, Guo-Chen, et al.
Publicado: (2016)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
por: Chen, Wanghua, et al.
Publicado: (2018)

Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis
por: Zhu, Jinfeng, et al.
Publicado: (2019)

Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer—A Promising Signaling Network for Therapeutic Interventions
por: Güllülü, Ömer, et al.
Publicado: (2021)

Kurzzeitstrahlentherapie mit 5 × 5 Gy gefolgt von präoperativer Chemotherapie und Resektion bei Patienten mit lokal fortgeschrittenen Rektumkarzinomen führt zu einer Verbesserung des krankheitsfreien Überlebens
por: Kirste, Simon, et al.
Publicado: (2021)

Kein Vorteil für die lokale Kontrolle nach Dosiseskalation der Strahlentherapie bei Patienten mit Ösophaguskarzinom nach einer definitiven Radiochemotherapie: randomisierte Phase-III-Studie ARTDECO
por: Fokas, Emmanouil, et al.
Publicado: (2022)

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Adding Consolidation Capecitabine to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Propensity-Matched Comparative Study
por: Fang, Yifang, et al.
Publicado: (2022)

A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
por: Jo, Hyunji, et al.
Publicado: (2023)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy
por: Rödel, Franz, et al.
Publicado: (2016)

Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models
por: Li, Moying, et al.
Publicado: (2022)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bkom3960uhjme52kc1011dd15q